[1]王逸飞,王 志,左宏波,等.伊利替康联合替吉奥在晚期结直肠癌治疗的临床研究[J].医学信息,2019,32(07):158-159.[doi:10.3969/j.issn.1006-1959.2019.07.049]
　WANG Yi-fei,WANG Zhi,ZUO Hong-bo,et al.Clinical Study of Irinotecan Combined with Tegafur,Gimeracil and Oteracil Porassium Capsulesin the Treatment of Advanced Colorectal Cancer[J].Journal of Medical Information,2019,32(07):158-159.[doi:10.3969/j.issn.1006-1959.2019.07.049]
点击复制

伊利替康联合替吉奥在晚期结直肠癌治疗的临床研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年07期
页码:
158-159
栏目:
药物与临床
出版日期:
2019-04-01

文章信息/Info

Title:
Clinical Study of Irinotecan Combined with Tegafur,Gimeracil and Oteracil Porassium Capsulesin the Treatment of Advanced Colorectal Cancer
文章编号:
1006-1959（2019）07-0158-02
作者:
王逸飞; 王 志; 左宏波; 李言冰
（九江市第一人民医院肿瘤科，江西 九江 332000）
Author(s):
WANG Yi-fei; WANG Zhi; ZUO Hong-bo; LI Yan-bing
(Department of Oncology,Jiujiang No.1 People's Hospital,Jiujiang 332000,Jiangxi,China)
关键词:
结直肠癌; 伊利替康; 替吉奥; 不良反应
Keywords:
Colorectal cancer; Irinotecan; Tegafur; Gimeracil and Oteracil Porassium Capsules;  Adverse reactions
分类号:
R97;R73
DOI:
10.3969/j.issn.1006-1959.2019.07.049
文献标志码:
A
摘要:
目的 评价晚期结直肠癌患者采用伊立替康联合替吉奥治疗的临床疗效。方法 选取2015年4月~2017年12月我院肿瘤科收治的60例晚期初治结直肠癌患者作为研究对象，根据治疗方案的不同分为联合治疗组（32例）和对照组（28例）。对照组采用伊立替康治疗方案，在对照组基础上联合治疗组联合替吉奥治疗方案，比较两组的不良反应发生率及疗效情况。结果 治疗后，联合治疗组的临床有效率高于对照组，差异有统计学意义(P＜0.05)；两组患者的主要不良反应比较，联合治疗组白细胞减少及胃肠道反应发生率较对照组降低，差异具有统计学意义(P＜0.05)。结论 晚期结直肠癌患者采用伊立替康联合替吉奥治疗方案优于单独采用伊立替康治疗方案，提高临床治疗的有效率，降低白细胞减少及胃肠道等不良反应的发生率。
Abstract:
Objective To evaluate the clinical efficacy of irinotecan plusTegafur,Gimeracil and Oteracil Porassium Capsulesin patients with advanced colorectal cancer.Methods 60 patients with advanced primary colorectal cancer admitted to our department of oncology from April 2015 to December 2017 were enrolled in the study. They were divided into the combination treatment group (32 cases) and the control group (28 cases).The control group was treated with irinotecan. On the basis of the control group, the combined treatment group was treated with a combination of Tegafur,Gimeracil and Oteracil Porassium Capsulesand the incidence of adverse reactions and efficacy were compared between the two groups. Results After treatment, the clinical effective rate in the combined treatment group was higher than that in the control group, the difference was statistically significant (P<0.05). The main adverse reactions in the two groups were compared with the leukopenia in the combined treatment group. The incidence of gastrointestinal reactions was lower than that of the control group,the difference was statistically significant (P<0.05). Conclusion The treatment of irinotecan plus Tegafur,Gimeracil and Oteracil Porassium Capsules in patients with advanced colorectal cancer is superior to irinotecan alone in improving the efficiency of clinical treatment and reducing the incidence of leukopenia and gastrointestinal reactions.

参考文献/References:


[1]季华.FOLFOX4化疗联合自拟中药扶正消积汤治疗中晚期结肠癌疗效观察[J].现代中西医结合杂志,2016,25(21):2363-2365.
[2]陈幸运,周礼鲲,王霞,等.维持治疗在晚期结直肠癌化疗后达稳定患者中的价值及预后分析[J].中国肿瘤临床,2016,43(2):76-80.
[3]尹进南,徐进,岳茂兴,等.K-ras突变型晚期结直肠癌患者采用奥沙利铂或伊立替康联合氟尿嘧啶治疗的临床对比研究[J].临床和实验医学杂志,2017,16(9):73-76.
[4]左文丽,邓梅,尹青松,等.门冬酰胺酶联合GDP方案治疗结外NK/T细胞淋巴瘤的临床疗效观察[J].中国肿瘤临床,2017,44(7):321-323.
[5]Fiala O,Buchler T,Mohelnikova-DuchonowaB,et al.G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab[J].Tumour Biol,2016,37(5):6823-6830.
[6]蔡红许,宋竹翠,林灵芝,等.替吉奥联合伊立替康或紫杉醇治疗晚期进展胃癌疗效分析[J].河北医药,2017,39(24):3754-3756.
[7]苏正曙,陈建望,孙余挺.替吉奥联合奥沙利铂一线治疗晚期结直肠癌的临床分析[J].实用肿瘤杂志,2017,32(1):77-79.
[8]孟秋丽,吴晓邡.替吉奥单药治疗老年或体弱转移性结直肠癌患者疗效分析[J].肿瘤基础与临床,2016,29(1):39-42.
[9]周冬梅,韩正祥,杜秀平,等.替吉奥联合伊立替康治疗FOLFOX 耐药的晚期结直肠癌的临床研究［J］．肿瘤药学,2014,4(5):350-353.
[10]颜芳,孟荣荣.替吉奥胶囊联合伊立替康治疗晚期结直肠癌的临床观察[J]．实用临床医药杂志,2013,17(1):70-72.
[11]焦勇.替吉奥联合伊立替康一线治疗晚期结直肠癌的前瞻性临床观察[J].北方药学,2016,13(1):16-17.

相似文献/References:

[1]张西园.糖尿病与结直肠癌患者预后相关研究进展[J].医学信息,2018,31(01):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
　ZHANG Xi-yuan.Research Progress in the Relationship between Diabetes and the Prognosis of Colorectal Cancer[J].Journal of Medical Information,2018,31(07):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
[2]陈学敏,彭 琼.中性粒细胞与淋巴细胞比值联合癌胚抗原对结直肠癌早期诊断的研究[J].医学信息,2019,32(02):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
　CHEN Xue-min,PENG Qiong.Early Diagnosis of Colorectal Cancer by Neutrophil-lymphocyte Ratio Combined with Carcinoembryonic Antigen[J].Journal of Medical Information,2019,32(07):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
[3]李在明,魏正强.外泌体在结直肠癌中的研究进展[J].医学信息,2019,32(03):42.[doi:10.3969/j.issn.1006-1959.2019.03.014]
　LI Zai-ming,WEI Zheng-qiang.Research Progress of Exosomes in Colorectal Cancer[J].Journal of Medical Information,2019,32(07):42.[doi:10.3969/j.issn.1006-1959.2019.03.014]
[4]周玲玲,鞠乐乐,颜 玉.结直肠癌患者手术前后血清IGF-1水平变化及临床价值分析[J].医学信息,2019,32(04):121.[doi:10.3969/j.issn.1006-1959.2019.04.039]
　ZHOU Ling-ling,JU Le-le,YAN Yu.Analysis of Changes and Clinical Value of Serum IGF-1 Levels in Patients with Colorectal Cancer before and after Operation[J].Journal of Medical Information,2019,32(07):121.[doi:10.3969/j.issn.1006-1959.2019.04.039]
[5]陈小玉,白 鍊,贺春香.结直肠癌根治手术患者营养状况调查[J].医学信息,2019,32(05):83.[doi:10.3969/j.issn.1006-1959.2019.05.025]
　CHEN Xiao-yu,BAI Lian,HE Chun-xiang.Investigation on Nutritional Status of Patients Undergoing Radical Surgery for Colorectal Cancer[J].Journal of Medical Information,2019,32(07):83.[doi:10.3969/j.issn.1006-1959.2019.05.025]
[6]李大略,赵资文,刘兆礼,等.加速康复外科对合并有糖尿病的结直肠癌患者术后炎症反应与营养代谢的影响[J].医学信息,2019,32(07):67.[doi:10.3969/j.issn.1006-1959.2019.07.021]
　LI Da-lue,ZHAO Zi-wen,LIU Zhao-li,et al.Effect of Accelerated Rehabilitation Surgery on Postoperative Inflammatory Response and Nutrient Metabolism in Patients with Colorectal Cancer Complicated with Diabetes[J].Journal of Medical Information,2019,32(07):67.[doi:10.3969/j.issn.1006-1959.2019.07.021]
[7]谢 勇,涂经楷,肖明盛,等.腹腔镜与传统开腹结直肠癌根治术手术效果对比[J].医学信息,2019,32(11):98.[doi:10.3969/j.issn.1006-1959.2019.11.026]
　XIE Yong,TU Jing-kai,XIAO Ming-sheng,et al.Comparative of Laparoscopic and Traditional Open Radical Rectal Cancer Radical Operation[J].Journal of Medical Information,2019,32(07):98.[doi:10.3969/j.issn.1006-1959.2019.11.026]
[8]符青云,欧阳小明,郅 程,等.结直肠癌组织EGFR、BRAF及NRAS基因突变检测及临床意义分析[J].医学信息,2022,35(13):83.[doi:10.3969/j.issn.1006-1959.2022.13.018]
　FU Qing-yun,OUYANG Xiao-ming,ZHI Cheng,et al.Detection and Clinical Significance of EGFR, BRAF and NRAS Gene Mutations in Colorectal Cancer[J].Journal of Medical Information,2022,35(07):83.[doi:10.3969/j.issn.1006-1959.2022.13.018]
[9]李莎莎,李 芳,王卫峰,等.地中海饮食与结直肠癌的相关研究[J].医学信息,2019,32(15):6.[doi:10.3969/j.issn.1006-1959.2019.15.003]
　LI Sha-sha,LI Fang,WANG Wei-feng,et al.Correlation between Mediterranean Diet and Colorectal Cancer[J].Journal of Medical Information,2019,32(07):6.[doi:10.3969/j.issn.1006-1959.2019.15.003]
[10]孙 峰,鲍扬漪,朱 婷,等.晚期结直肠癌抗血管生成靶向治疗研究进展[J].医学信息,2019,32(17):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]
　SUN Feng,BAO Yang-yi,ZHU Ting,et al.Advances in Anti-angiogenesis Targeted Therapy for Advanced Colorectal Cancer[J].Journal of Medical Information,2019,32(07):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]

更新日期/Last Update: 2019-04-01